Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 3 2Phase NA 1

Status

Completed 7Recruiting 4Active not recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Inflammatory Breast Neoplasms 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 48Radiotherapy 47Docetaxel 41Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Drug Therapy 14Irinotecan 13Imatinib Mesylate 13Filgrastim 13Zoledronic Acid 12Radiosurgery 12Erlotinib Hydrochloride 12Trastuzumab 11Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Dexrazoxane × Clear all
NCT00016276 2013-01-16

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
396 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Cardiotoxicity

NCT00165087 2007-12-28

Treatment of Childhood Acute Lymphoblastic Leukemia

Dana-Farber Cancer Institute

Phase 3 Terminated
491 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡